Efficacy And SafetyData from CAHmelia-203 could substantially de-risk tildacerfont on both efficacy and safety ahead of data from the registration-enabling CAHmelia-204 trial.
Enrollment TargetsAll three trials surpassed their enrollment targets, which is a positive sign of patient enthusiasm for tildacerfont and management execution with the benefit of additional statistical cushioning.
Strategic CollaborationSpruce Biosciences and HMNC Brain Health GmbH announced a strategic collaboration to develop Spruce’s lead investigational product candidate, tildacerfont, for the treatment of major depressive disorder.